Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

NCT00085904 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor Cancer
Lymphoma

Interventions

DRUG: SB-485232

Sponsor

GlaxoSmithKline